Fast Five Quiz: Test Your Knowledge of Human Papillomavirus

William James, MD


September 29, 2017

The following are 2015 guidelines on HPV screening and management from a guidance panel cosponsored by the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology:

  • A negative high-risk HPV test provides greater reassurance of a low risk for CIN grade 3 or cancer (CIN3+) than does a negative cytology result.

  • Because of equivalent or superior effectiveness, primary high-risk HPV screening can be considered an alternative to current US cytology-based cervical cancer screening methods. Cytology alone and co-testing remain the screening options specifically recommended in major guidelines.

  • On the basis of limited data, triage of high-risk HPV-positive women using a combination of genotyping for HPV 16 and 18 and reflex cytology for women positive for the 12 other high-risk HPV genotypes appears to be a reasonable approach to managing high-risk HPV-positive women.

  • Rescreening after a negative primary high-risk HPV screen should occur no sooner than every 3 years.

  • Primary high-risk HPV screening should not be initiated before age 25 years.

  • Although primary HPV screening at age 25-29 years may increase CIN3 detection, further research is needed to determine the effect of increased number of colposcopies, integration with screening before age 25 years, and actual effect on cancer prevention.

New guidelines for primary prevention of cervical cancer and screening to prevent invasive cervical cancer were also recently published by the American Society of Clinical Oncology.

For more on the workup of HPV, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.